At PharmSci 360, Insilica CEO Thomas Luechtefeld will present on auditable agentic AI systems and how they are expanding computational toxicology beyond single predictive models.
|Articles|May 15, 2002
- BioPharm International-05-01-2002
- Volume 15
- Issue 5
Analytical Advances: Strategies in Clarifying Mammalian Cultures
Author(s)Charles Lambalot
by Charles Lambalot, Millipore Corporation
Advertisement
Articles in this issue
over 24 years ago
Info+over 24 years ago
Analytical Advances: Using Image Informatics - Focusing Proteomicsover 24 years ago
The Not-So-Sure Thingover 24 years ago
Washington Report: Vaccine Shortages put Spotlight on Productionover 24 years ago
Guest Editorial: Validation Bingoover 24 years ago
Travel Notes: Yes, Virginia, There is Biotech in the CommonwealthAdvertisement
Related to this article
BMS's Dr Nathan Pennell outlines how biomarker testing barriers and trial diversity affect patient access to targeted oncology drugs.
Advertisement
Advertisement
Trending on BioPharm International
1
Zylidac Bio to Scale Prolific's Optogenetic Cell Line Platform to GMP
2
BioNTech, BMS to Pair Pumitamig With Trodelvy in Phase 3 First-Line TNBC Trial
3
Sanofi Begins Construction of EU-Backed Insulin Plant in Frankfurt
4
TaiMed’s Anti-CD4 Antibody TMB-365 Reduces HIV Viral Load in Phase 1, Supporting Long-Acting Combination Regimens
5